Literature DB >> 25342145

High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses.

Rajini Mudhasani1, Krishna P Kota1, Cary Retterer1, Julie P Tran1, Sarah R Tritsch1, Rouzbeh Zamani1, Chris A Whitehouse1, Sina Bavari2.   

Abstract

High-content image-based screening was developed as an approach to test a small-molecule library of compounds targeting signal transduction pathways for antiviral activity against multiple highly pathogenic RNA viruses. Of the 2843 compounds screened, 120 compounds exhibited ≥60% antiviral activity. Four compounds (E225-0969, E528-0039, G118-0778, and G544-0735), which were most active against Rift Valley fever virus (RVFV) and showed broad-spectrum antiviral activity, were selected for further evaluation for their concentration-response profile and cytotoxicity. These compounds did not show any visible cytotoxicity at the highest concentration of compound tested (200 µM). All four of these compounds were more active than ribavirin against several viruses. One compound, E225-0969, had the lowest effective concentration (EC50 = 1.9-8.92 µM) for all the viruses tested. This compound was 13- and 43-fold more inhibitory against RVFV and Chikungunya virus (CHIKV), respectively, than ribavirin. The highest selectivity index (>106.2) was for E225-0969 against CHIKV. Time-of-addition assays suggested that all four lead compounds targeted early steps in the viral life cycle (entry and/or replication) but not virus egress. Overall, this work demonstrates that high-content image analysis can be used to screen chemical libraries for new antivirals against highly pathogenic viruses.
© 2014 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  antiviral drugs; cell-based assays; fluorescence methods; high-content screening

Mesh:

Substances:

Year:  2014        PMID: 25342145     DOI: 10.1177/1087057114556253

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  6 in total

Review 1.  Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection.

Authors:  Colm Atkins; Alexander N Freiberg
Journal:  Future Virol       Date:  2017-10-23       Impact factor: 1.831

2.  Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.

Authors:  Ashwini Brahms; Rajini Mudhasani; Chelsea Pinkham; Krishna Kota; Farooq Nasar; Rouzbeh Zamani; Sina Bavari; Kylene Kehn-Hall
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

3.  Strategies for Validation of Inactivation of Viruses with Trizol® LS and Formalin Solutions.

Authors:  Cary Retterer; Tara Kenny; Rouzbeh Zamani; Louis A Altamura; Brian Kearney; Jim Jaissle; Susan Coyne; Scott Olschner; David Harbourt
Journal:  Appl Biosaf       Date:  2020-06-01

4.  Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

Authors:  Alex P Salam; Alexandre Duvignaud; Marie Jaspard; Denis Malvy; Miles Carroll; Joel Tarning; Piero L Olliaro; Peter W Horby
Journal:  PLoS Negl Trop Dis       Date:  2022-03-30

5.  Protein Kinase R Degradation Is Essential for Rift Valley Fever Virus Infection and Is Regulated by SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 Ligase.

Authors:  Rajini Mudhasani; Julie P Tran; Cary Retterer; Krishna P Kota; Chris A Whitehouse; Sina Bavari
Journal:  PLoS Pathog       Date:  2016-02-02       Impact factor: 6.823

Review 6.  Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.

Authors:  Shuvam Chaudhuri; Julian A Symons; Jerome Deval
Journal:  Antiviral Res       Date:  2018-05-15       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.